Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase

British Journal of Cancer

Volumn 91, Issue 4, 2004, Pages 699-702

  Deichmann, M ^a   Kahle, B ^a   Moser, K ^a   Wacker, J ^a   Wust K ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

American Joint Committee on Cancer stage IV; C reactive protein (CRP); Lactate dehydrogenase (LDH); Melanoma; Serum marker; Tumour marker

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; LACTATE DEHYDROGENASE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CANCER GRADING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME ASSAY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MALE; MEASUREMENT; MELANOMA; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RANK SUM TEST; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL SIGNIFICANCE;

EID: 4344701616     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602043     Document Type: Article

References (28)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648
2. Blay JY, Negrier S, Combarel V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF (1992) Serum level of inlerteukin 6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322
3. Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich PC (1989) Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 242: 237-239
4. Colombo MP, Maccalli C, Mattei S, Melani C, Radrizzani M, Parmiani G (1992) Expression of cytokine genes, including 11-6, in human malignant melanoma cell lines. Melanoma Res 2: 181-189
5. Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, Näher H (1999) S100β, MIA and LDH discriminate progressive from non-progressive AJCC stage IV melanoma disease. J Clin Oncol 17: 1891-1896
6. Deichmann M, Benner A, Jäckel A, Bock M, Waldmann V, Näher H (2000) Elevated interleukin-6 serum levels indicate progressive disease in metastasized malignant melanoma. J Exp Clin Cancer Res 19: 301-307
7. Deichmann M, Benner A, Kuner N, Wacker J, Waldmann V, Näher H (2001) Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100β or melanoma inhibitory activity (MIA)? Melanoma Res 11: 291-296
8. Eton O, Legha SS, Moon TE, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS (1998) Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16: 1103-1111
9. Francis GM, Krohn EG, Woods KV, Buzaid AC, Grimm EA (1996) Interleukin-6 production and secretion in human melanoma cell lines, regulation by inlerleukin-1. Melanoma Res 6: 191-201
10. Franzke A, Probst-Kepper M, Buer J, Duensing S, Hoffmann R, Wittke F, Volkenandt M, Ganser A, Atzpodien J (1998) Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 78: 40-45
11. Gough DB, Fearon KC, Carter DC (1996) Metabolic disturbance and sensitivity to endoloxin in patients with advanced cancer, relationship to lymphocyte reactivity, tumour necrosis factor production and survival. Clin Exp Immunol 105: 529-536
12. Hanley JA, McNeil BJ (1983) A method of comparing te areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843
13. Hirano T (1992) Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 62: S60-S65
14. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, Goey SH, Gore M, Dorval T, Hancock B, Punt CJ, Dummer R, Avril MF, Brocker EB, Benhammouda A, Eggermont AM, Pritsch M (1998) Results of interleukin-2-based treatment in advanced melanoma, a case record-based analysis of 631 patients. J Clin Oncol 16: 2921-2929
15. Kishimoto T (1989) The biology of interleukin-6. Blood 74: 1-10
16. Klein B, Wijdens J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu ZY, Mannoni P, Sany J, Bataille R (1991) Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78: 1198-1204
17. Lee JD, Sievers TM, Skotzko M, Chandler CF, Morton DL, McBride WH, Econoumou JS (1992) Interleukin-6 production by human melanoma cell lines. Lymphokine Cytokine Res 11: 161-166
18. Lu C, Kerbel RS (1993) Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 120: 1281-1288
19. Mahmoud FA, Rivera NI (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4: 250-255
20. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M (1994) Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56: 853-857
21. Moshage HJ, Roclofs HMJ, van Pelt JF, Hazenberg BPC, van Leeuwen MA, Limburg PC, Aarden LA, Yap SH (1988) The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 155: 112-117
22. Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C, Weil M, Khayat D, Soubrane C (1996) Endogenous interleukin 6 levels in patients with metastatic malignant melanoma, correlation with tumor burden. Clin Cancer Res 2: 1405-1409
23. Nozoe T, Matsumata T, Kitamura M, Sugimachi K (1998) Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176: 335-338
24. Pepys MB (1995) The acute phase response and C-reactive protein. In Oxford Textbook of Medicine, Weatherall DJ, Ledingham JGG, Warrell DA (eds) pp 1527-1533, Oxford: Oxford University Press
25. Rigel DS, Frieman RJ, Kopf AW (1996) The incidence of malignant melanoma in the United States, issues as we approach the 21st century. J Am Acad Dermatol 34: 839-847
26. Sirott M, Bajorin D, Wong G, Tao Y, Chapman PB, Templeton MA, Houghton AN (1993) Prognostic factors in patients with metastatic malignant melanoma, a multivariate analysis. Cancer 72: 3091-3098
27. Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, Deneux L, Gorin I, Negrier S, Mathiot C, Pouillart P, Fridman WH (1996) Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 14: 1697-1703
28. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux I, Pouillart P, Fridman WH (1994) Serum interleukin 6 and C-reactive protein levels correlate with resistance to 11-2 therapy and poor survival in melanoma patients. Br J Cancer 69: 9111-9913